CDK4 and neoplasm: miR‐206 directly targets CDK6 in the RAS signaling pathway, and its introduction into PM cells inhibits tumor growth; this effect is further enhanced when combined with the cyclin‐dependent kinases 4 and 6 (CDK4/6) inhibitor abemaciclib [181].